In this study, we propose for the first time the combined use of the SERS and Raman technologies to test their performance to identify and quantitate HER2 expression in two selected BC cell lines, SKBR3 and MDA-MB-468, exhibiting the highest and lowest levels of HER2 expression, respectively, together with MCF10A, a non-tumorigenic cell line from the normal breast epithelium. Here, ERBB2 is linked to breast cancer.